**

**

**iBio Updates Corporate Presentation in Recent 8-K Filing**

In a recent 8-K filing to the Securities and Exchange Commission, iBio, Inc. announced updates to its corporate presentation. The filing, dated January 10, 2025, highlighted key developments within the company, shedding light on its current progress and strategic advancements.

The company presented a range of activities aimed at enhancing its corporate presentation. Notably, iBio, in collaboration with AstralBio Inc., showcased the successful development of an antibody targeting Activin E. This innovation represents a significant advancement in the therapeutic targeting of cardiometabolic disorders and obesity, utilizing the company’s patented Machine-Learning Antibody Engine. Preclinical studies demonstrated the efficacy of the antibody in binding to Activin E and blocking its signaling, showcasing exceptional potency.

Furthermore, the company disclosed its focus on advancing its corporate presentation for interactions with investors, analysts, and other stakeholders. Specific slides within the presentation highlighted advancements in their pipeline, including the development of novel antibodies targeting various epitopes and proteins associated with metabolic health and oncology.

The filing also provided insights into the financial standing of iBio, disclosing key figures such as $11.3 million in cash and restricted cash as of September 30, 2024. The company’s financial runway was indicated to extend into the first quarter of fiscal year 2026, with 9.1 million outstanding shares as of November 21, 2024.

While the update to the corporate presentation signals iBio’s ongoing commitment to innovation and progress, the company emphasized that the information contained in the filing and presentation is subject to certain forward-looking statements and risks. It reiterated that the details shared should not be considered as filed for Securities Act purposes or incorporated by reference into subsequent filings.

The continuous evolution and enhancement of its corporate presentation align with iBio’s strategic vision and efforts towards developing pioneering solutions in the biopharmaceutical sector.

This news was brought to light through the company’s recent Form 8-K filing, showcasing its dedication to transparency and communication with stakeholders within the financial community.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read iBio’s 8K filing here.

iBio Company Profile

iBio, Inc, a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.